Foresite Capital Management V, LLC purchased $2.5M of LTGO (indirect holdings)
Foresite Capital Management V, LLC purchased 140,000 indirectly-held shares of Latigo Biotherapeutics, Inc. (LTGO) at $18.00 ($2.52M total) on 2026-08-10.
How this was made
The 30-second read
Why it matters
Traders may treat the disclosed $2.52M open-market purchase by a 10% owner as a modest positive sentiment input, but it is not a fundamental catalyst.
Market read
A disclosed purchase increases LTGO holdings to 2,008,024 shares after buying 140,000 shares at $18.00 on 2026-08-10.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but it also provides no rationale for the trade, and the transaction occurred at a stated $18/share price without linking to new company news.
Background
The article is a SEC Form 4 insider transaction disclosure for Latigo Biotherapeutics, Inc.
Ticker impact
Latigo Biotherapeutics disclosed a Form 4 showing Foresite Capital Management V bought 140,000 shares of LTGO for $2.52M on 2026-08-10.
Likely limited near-term impact; could modestly support sentiment if traders view it as a confidence signal.
Form 4 purchases can be read as bullish, but the article provides no new fundamentals, guidance, or event beyond the transaction details.
Market effects
No clear sector read-through because the filing is company-specific and does not cite clinical, regulatory, or financing developments.
None indicated; the disclosure is US-focused and does not reference broader regional catalysts.
None indicated; no international deal, regulator, or supply-chain event is mentioned.
Counterpoint
A purchase by a large holder does not guarantee near-term outperformance, especially without context on valuation, liquidity needs, or diversification.
Key entities
- issuerLatigo Biotherapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- 10% ownerForesite Capital Management V, LLC
Reported the indirect open-market purchase of LTGO shares.
